Tysabri and PML: What Patients in New Jersey Should Know About Long-Term Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical for long-term safety. The medical community has long recognized that certain risk factors, such as JC virus antibody status and duration of therapy, influence PML onset. This page outlines the key risk factors to review and what monitoring steps are recommended for patients in New Jersey.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus. PML typically occurs only in patients who are immunocompromised and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, to communicate this risk. The clinical presentation of PML is variable and can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, memory loss, and visual changes. In the FDA Adverse Event Reporting System (FAERS), the most frequently reported adverse events associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, asthenia, balance disorder, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports are not specific to PML, they reflect the types of neurological symptoms that may be early indicators of the disease. Diagnosis of PML requires a high index of suspicion and is confirmed by brain MRI showing demyelinating lesions and detection of JC virus DNA in cerebrospinal fluid or brain biopsy.

Mechanism of PML Development and Risk Factors

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking the migration of immune cells, particularly lymphocytes, into the central nervous system. This immunosuppressive effect reduces the normal immune surveillance that controls JC virus replication. In the setting of reduced immune surveillance, latent JC virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The FDA has identified three specific risk factors that increase the likelihood of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment. The adequacy of warnings regarding Tysabri and PML is a critical issue for affected patients and their families. The boxed warning explicitly states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. The warning also mandates that Tysabri dosing be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients are informed of the risks and that monitoring occurs.

Legal Implications for Patients Who Develop PML

For patients who develop PML, the timeline between exposure and documented harm can vary. PML can occur after a variable duration of Tysabri therapy, with risk increasing after two years of treatment. The latency period between JC virus reactivation and clinical symptoms may be weeks to months, and early diagnosis is challenging because initial symptoms can mimic a multiple sclerosis relapse. For patients who have developed PML after Tysabri treatment, attorney-related considerations may include evaluating whether the prescribing physician adequately assessed risk factors, provided appropriate monitoring, and promptly recognized and acted upon early symptoms. The boxed warning and the TOUCH program establish a standard of care that includes risk stratification based on anti-JCV antibody status, treatment duration, and prior immunosuppressant use. Failure to adhere to these standards could be relevant in legal claims. Additionally, the timing of symptom onset relative to treatment initiation and the presence of any missed opportunities for earlier diagnosis are important factors. Patients and their families may seek legal counsel to explore whether there was a failure to warn or a deviation from accepted medical practice that contributed to the harm. In summary, Tysabri is associated with a known risk of PML, a devastating brain infection. The FDA has mandated strong warnings and a restricted distribution program to mitigate this risk. For patients who develop PML, the clinical presentation, risk factors, and timeline of exposure are central to both medical management and legal evaluation. Understanding these elements is essential for affected individuals and their legal representatives.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the early symptoms of PML in Tysabri patients?

Early symptoms include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, memory loss, and visual changes. These can mimic multiple sclerosis relapse, making diagnosis challenging (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

What legal options exist for patients who developed PML after Tysabri?

Patients may seek legal counsel to evaluate whether healthcare providers failed to adequately assess risk factors, monitor for symptoms, or provide timely diagnosis. The boxed warning and TOUCH program establish standards of care that, if breached, could support legal claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.